The Effect of Ginkgolide on Clinical Improvement of Patients With Acute Ischemic Stroke

The aim of this study is to evaluate the safety and effectivity of Ginkgo diterpene lactone meglumine injection tn the treatment of acute ischemic stroke

Inclusion Criteria:Aged > 40 years, and gender not limited;Within 48 hours of stroke onset of ischemic stroke;The first onset, or always not obvious legacy of stroke sequela;A score of 5-24 points on the National Institute of Health Stroke Scale (NIHSS)；Understand and voluntarily signed informed consent.Exclusion Criteria:Cardiogenic cerebral embolism;AIS caused by other definite causes (e.g., arterial dissection, vasculitis, vascular malformation, etc.) or undetermined etiology;Treated with thrombolysis or intravascular therapy, or with arteriovenous bridging after onset;Under dual antiplatelet therapy or anticoagulant therapy;A score of more than 2 on the modified Rankin Scale (mRS) (scores range from 0 [no symptoms] to 6 [death]) before the occurrence of AIS;Allergy or contraindication to GDLI or aspirin;Patients with active bleeding or bleeding tendency, malignancies, severe liver (the serum level of AST and/or ALT > 2 times the upper limit of normal), or renal failure (the serum level of creatinine > 1.5 times the upper limit of normal or GFR < 40 ml/min/1.73m2);Anticipated requirement for long-term nonstudy antiplatelet drugs or for nonsteroidal anti-inflammatory drugs affecting platelet function;Severe noncardiovascular coexisting condition, with a life expectancy of less than 3 months;Planned surgery or interventional treatment requiring cessation of the study drug;Pregnancy, lactation, or planning to get pregnant.